{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:02:01Z","timestamp":1787724121727,"version":"build-2784847793"},"reference-count":78,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2017,10,6]],"date-time":"2017-10-06T00:00:00Z","timestamp":1507248000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1111\/cts.12499","type":"journal-article","created":{"date-parts":[[2017,10,7]],"date-time":"2017-10-07T04:06:35Z","timestamp":1507349195000},"page":"251-260","source":"Crossref","is-referenced-by-count":64,"title":["Role of CYP3A in Oral Contraceptives Clearance"],"prefix":"10.1111","volume":"11","author":[{"given":"Nan","family":"Zhang","sequence":"first","affiliation":[{"name":"Office of Clinical Pharmacology (OCP), Office of Translational Sciences (OTS) Center for Drug Evaluation and Research (CDER) US Food and Drug Administration (FDA) Silver Spring Maryland USA"},{"name":"Oak Ridge Institute for Science and Education (ORISE) Tennessee Oak Ridge USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihong","family":"Shon","sequence":"additional","affiliation":[{"name":"Office of Clinical Pharmacology (OCP), Office of Translational Sciences (OTS) Center for Drug Evaluation and Research (CDER) US Food and Drug Administration (FDA) Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myong\u2010Jin","family":"Kim","sequence":"additional","affiliation":[{"name":"Office of Clinical Pharmacology (OCP), Office of Translational Sciences (OTS) Center for Drug Evaluation and Research (CDER) US Food and Drug Administration (FDA) Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongwoo","family":"Yu","sequence":"additional","affiliation":[{"name":"Office of Clinical Pharmacology (OCP), Office of Translational Sciences (OTS) Center for Drug Evaluation and Research (CDER) US Food and Drug Administration (FDA) Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Office of Clinical Pharmacology (OCP), Office of Translational Sciences (OTS) Center for Drug Evaluation and Research (CDER) US Food and Drug Administration (FDA) Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiew\u2010Mei","family":"Huang","sequence":"additional","affiliation":[{"name":"Office of Clinical Pharmacology (OCP), Office of Translational Sciences (OTS) Center for Drug Evaluation and Research (CDER) US Food and Drug Administration (FDA) Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LaiMing","family":"Lee","sequence":"additional","affiliation":[{"name":"Office of Clinical Pharmacology (OCP), Office of Translational Sciences (OTS) Center for Drug Evaluation and Research (CDER) US Food and Drug Administration (FDA) Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doanh","family":"Tran","sequence":"additional","affiliation":[{"name":"Office of Clinical Pharmacology (OCP), Office of Translational Sciences (OTS) Center for Drug Evaluation and Research (CDER) US Food and Drug Administration (FDA) Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[{"name":"Office of Clinical Pharmacology (OCP), Office of Translational Sciences (OTS) Center for Drug Evaluation and Research (CDER) US Food and Drug Administration (FDA) Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,10,6]]},"reference":[{"key":"e_1_2_11_1_1","volume-title":"NCHS Data Brief","author":"Daniels K.","year":"2014"},{"key":"e_1_2_11_2_1","volume-title":"Contraceptive Technology: Twentieth Revised Edition","author":"Hatcher R.A.","year":"2011"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200746020-00003"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2007.09.025"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/0010-7824(90)90093-B"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/1479-7364-5-1-61"},{"key":"e_1_2_11_7_1","unstructured":"FDA. Drug development and drug interactions: table of substrates inhibitors and inducers.https:\/\/www.fda.gov\/drugs\/developmentapprovalprocess\/developmentresources\/druginteractionslabeling\/ucm093664.htm(2016)."},{"key":"e_1_2_11_8_1","unstructured":"FDA Guidance for Industry: (Draft Guidance) Drug Interaction Studies\u2014Study Design Data Analysis Implications for Dosing and Labeling Recommendations. US Food and Drug Administration.https:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm064982.htm(2012)."},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2013.772579"},{"key":"e_1_2_11_10_1","unstructured":"Agouron Pharmaceuticals Inc.Viracept (nelfinavir mesylate) tablets and oral powder product labeling. US Food and Drug Administration.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2005\/021503s006lbl.pdf(2011)."},{"key":"e_1_2_11_11_1","unstructured":"Merck & Co. Inc.Emend (aprepitant) capsules product labeling. US Food and Drug Administration.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021549s017lbl.pdf(2006)."},{"key":"e_1_2_11_12_1","unstructured":"Abbott Laboratories. Norvir (ritonavir) capsules soft gelatin for oral use product labeling. US Food and Drug Administration.https:\/\/dailymed.nlm.nih.gov\/dailymed\/archives\/fdaDrugInfo.cfm?archiveid=9385(1996)."},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2007.03084.x"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12745"},{"key":"e_1_2_11_15_1","unstructured":"Merck & Co. Inc. Crixivan (indinavir sulfate) capsules product labeling.https:\/\/dailymed.nlm.nih.gov\/dailymed\/archives\/fdaDrugInfo.cfm?archiveid=9419(2015)."},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270011419855"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-014-1711-0"},{"key":"e_1_2_11_18_1","unstructured":"Merck & Co. Inc.Victreli (boceprevir) capsules product labeling. US Food and Drug Administration.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/202258lbl.pdf(2011)."},{"key":"e_1_2_11_19_1","article-title":"Overview of FDA Approval Activities for Telithromycin","author":"Sanofi\u2010Aventis US. Ketek (telithromycin)","year":"2006","journal-title":"US Food and Drug Administration"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03589-14"},{"key":"e_1_2_11_21_1","unstructured":"PD\u2010Rx Pharmaceuticals. Diflucan (fluconazole tablets) product labeling. US Food and Drug Administration.http:\/\/druginserts.com\/lib\/rx\/meds\/diflucan\u20105\/page\/3\/(2011)."},{"key":"e_1_2_11_22_1","unstructured":"Bristol\u2010Myers Squibb Company.Reyataz (atazanavir sulfate) capsules product labeling. US Food and Drug Administration.https:\/\/dailymed.nlm.nih.gov\/dailymed\/archives\/fdaDrugInfo.cfm?archiveid=4548(2011)."},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-013-1857-9"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.377"},{"key":"e_1_2_11_25_1","unstructured":"Janssen Products.Olysio (simeprevir) capsules for oral use.https:\/\/www.olysio.com\/shared\/product\/olysio\/prescribing\u2010information.pdf(2016)."},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2011.595780"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.436"},{"key":"e_1_2_11_28_1","unstructured":"Sanofi\u2010Aventis U.S. LLC. Ketek (telithromycin): package insert and label information. US Food and Drug Administration.http:\/\/druginserts.com\/lib\/rx\/meds\/ketek\/(2010)."},{"key":"e_1_2_11_29_1","unstructured":"Bayer HealthCare Pharmaceuticals Inc. Yasmin (drospirenone\/ethinyl estradiol) tablets product labeling. US Food and Drug Administration.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/021098Orig1s022.pdf(2010)."},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2013.02.020"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.5414\/CPP44113"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/137192"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1725"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1999.tb00779.x"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1992.tb01773.x"},{"key":"e_1_2_11_36_1","unstructured":"Eisai Inc.Fycompa(perampanel) clinical pharmacology biopharmaceutics review. US Food and Drug Administration.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/202834Orig1s000TOC.cfm(2012)."},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2003.08.009"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2004.11.004"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1177\/009127009803801109"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(99)70138-4"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2003.55602.x"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1990.tb05457.x"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-012-1287-5"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2010.02917.x"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200204150-00007"},{"key":"e_1_2_11_46_1","unstructured":"Boehringer Ingelheim Pharmaceuticals. Viramune (nevirapine) tablets product labeling. US Food and Drug Administration.http:\/\/druginserts.com\/lib\/rx\/meds\/viramune\u20102\/(2005)."},{"key":"e_1_2_11_47_1","unstructured":"Novartis Pharmaceuticals Corporation. Trileptal (oxcarbazepine) tablets\/oral suspension product labeling. US Food and Drug Administration.http:\/\/medlibrary.org\/lib\/rx\/meds\/trileptal\/(2005)."},{"key":"e_1_2_11_48_1","unstructured":"Eisai Inc.Fycompa (perampanel) tablets product labeling. US Food and Drug Administration.https:\/\/www.drugs.com\/pro\/fycompa.html(2012)."},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0028-1095729"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.104.000182"},{"key":"e_1_2_11_51_1","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S0026-895X(25)13356-7","article-title":"Oxidation of 17 alpha\u2010ethynylestradiol by human liver cytochrome P\u2010450","volume":"33","author":"Guengerich F.P.","year":"1988","journal-title":"Mol. Pharmacol."},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.32.11.1299"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1093\/jb\/mvi047"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-0760(00)00125-4"},{"key":"e_1_2_11_55_1","unstructured":"Bayer HealthCare Pharmaceuticals Inc.Skyla (levonorgestrel\u2010releasing intrauterine system) product labeling. US Food and Drug Administration.http:\/\/druginserts.com\/lib\/rx\/meds\/skyla\/(2000)."},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/0010-7824(75)90094-3"},{"key":"e_1_2_11_57_1","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0090-9556(25)05712-5","article-title":"Excretion and stereoselective biotransformations of dl\u2010, d\u2010 and l\u2010norgestrel in women","volume":"3","author":"Sisenwine S.F.","year":"1975","journal-title":"Drug Metab. Dispos."},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.116.073940"},{"key":"e_1_2_11_59_1","volume-title":"18th Conference on Retroviruses and Opportunistic Infections,","author":"Kasserra C.","year":"2011"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.301.1.382"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2003.08.003"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.3109\/00498254.2013.820006"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.105.005447"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.104.002931"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/0960-0760(91)90129-S"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.112.049668"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.104.000794"},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.30.7.795"},{"key":"e_1_2_11_69_1","doi-asserted-by":"publisher","DOI":"10.2741\/3893"},{"key":"e_1_2_11_70_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.21.12208"},{"key":"e_1_2_11_71_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj3470321"},{"key":"e_1_2_11_72_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.212494599"},{"key":"e_1_2_11_73_1","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200424040-00001"},{"key":"e_1_2_11_74_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.31.7.908"},{"key":"e_1_2_11_75_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2012.00035"},{"key":"e_1_2_11_76_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-006-0096-0"},{"key":"e_1_2_11_77_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01716.x"},{"key":"e_1_2_11_78_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-005-0061-3"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcts.12499","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.12499","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T01:39:39Z","timestamp":1750901979000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.12499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,6]]},"references-count":78,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1111\/cts.12499"],"URL":"https:\/\/doi.org\/10.1111\/cts.12499","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,6]]}}}